RT Book, Section A1 Carr, Laurie L. A2 Grippi, Michael A. A2 Antin-Ozerkis, Danielle E. A2 Dela Cruz, Charles S. A2 Kotloff, Robert M. A2 Kotton, Camille Nelson A2 Pack, Allan I. SR Print(0) ID 1195013279 T1 Treatment of Non–Small-Cell Lung Cancer: Chemotherapy and Immunotherapy T2 Fishman’s Pulmonary Diseases and Disorders, 6e YR 2023 FD 2023 PB McGraw-Hill Education PP New York, NY SN 9781260473988 LK accessmedicine.mhmedical.com/content.aspx?aid=1195013279 RD 2024/03/28 AB Although lung cancer remains the leading cause of cancer death in the United States, a reduction in smoking rates and recent medical advances have improved the overall mortality rate. The decline in lung cancer mortality rates has accelerated from a 3% decrease (2008–2013) to 5% (2013–2017).1 Noted medical advances driving the decrease include lung cancer screening and stereotactic body radiotherapy. However, improved systemic therapy with immune checkpoint inhibitors and targeted agents also have had an impact. These improvements have led to prolonged survival in those with metastatic disease. Treatment with targeted agents or immunotherapy has led to a significant percentage of these patients surviving 5 years or more.2–4 These novel therapies have emerged to make lung cancer therapy better tolerated and more effective, even among those with significant comorbidities. Thus, although the morbidity and mortality of lung cancer remain high, novel approaches to therapy have begun to make a substantial impact.